Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Global Market Opportunities And Strategies To 2035

Peptide Therapeutics Contract Active Peptide Therapeutics Contract API Manufacturing Market Definition

Peptide Therapeutics Contract Active Peptide therapeutics contract API manufacturing refers to outsourced, specialized services that produce peptide-based active pharmaceutical ingredients for drug developers and pharmaceutical companies. These services typically include solid-phase or liquid-phase peptide synthesis, purification, characterization, scale-up, and GMP-compliant manufacturing to meet regulatory requirements for clinical and commercial use. The primary purpose of contract peptide API manufacturing is to enable reliable, high-quality, and scalable production of peptide drugs without requiring in-house manufacturing infrastructure. The peptide therapeutics contract API manufacturing market consists of sales, by entities (organizations, sole traders, or partnerships), of peptide therapeutics contract API manufacturing that used by pharmaceutical companies during drug development and commercial production. During the preclinical and clinical phases, peptide APIs are used for early research, toxicology testing, and clinical trial supplies.

Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Segmentation

The peptide therapeutics contract API manufacturing market is segmented by scale of operation, by synthesis method and by enterprise type.

By Scale Of Operation –
The peptide therapeutics contract API manufacturing market is segmented by scale of operation into:

• a) Preclinical Or Clinical
• b) Commercial

The commercial market was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation, accounting for 80.0% or $2,313.3 million of the total in 2025. Going forward, the preclinical or clinical segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation, at a CAGR of 7.8% during 2025-2030.

By Synthesis Method –
The peptide therapeutics contract API manufacturing market is segmented by synthesis method into:

• a) Non Chemical Synthesis
• b) Chemical Synthesis

The chemical synthesis was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method, accounting for 83.3% or $2,407.9 million of the total in 2025. Going forward, the non chemical synthesis segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method, at a CAGR of 8.7% during 2025-2030.

By Enterprise Type –
The peptide therapeutics contract API manufacturing market is segmented by enterprise type into:

• a) Large Enterprise
• b) Small And Medium Enterprises

The large enterprise market was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type, accounting for 66.7% or $1,929.1 million of the total in 2025. Going forward, the small and medium enterprises segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type, at a CAGR of 8.6% during 2025-2030.

By Geography - The peptide therapeutics contract API manufacturing market is segmented by geography into:

o Asia Pacific
• China
• India
• Japan
• Australia
• Indonesia
• South Korea
o North America
• USA
• Canada
o South America
• Brazil
o Western Europe
• France
• Germany
• UK
• Italy
• Spain
o Eastern Europe
• Russia
o Middle East
o Africa

North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market, accounting for 8.1% or $1,057.9 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market will be Asia Pacific and Africa where growth will be at CAGRs of 8.7% and 8.3% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 8.2% and 7.9% respectively.

Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Competitive Landscape

Major Competitors are:

Bachem Group

PolyPeptide Group

CordenPharma International GmbH

Ambiopharm Inc.

WuXi AppTec Co. Ltd.

Other Competitors Include:

Piramal Pharma Solutions (PPS)

Asymchem Laboratories (Tianjin) Co Ltd.

Cambrex Corporation

GenScript Biotech Corporation

BioDuro LLC

Thermo Fisher Scientific

Shanghai ChemPartner Co., Ltd.

Syngene International Limited

Auspep

Chinese Peptide Company Ltd.

CPC Scientific

ScinoPharm Taiwan, Ltd.

Lonza Australia

IDT Australia

SK pharmteco

Eli Lilly and Company

Anthem Biosciences Ltd

Neuland Laboratories Ltd

Sinopep-Allsino Biopharmaceutical Co., Ltd.

Zhejiang Jiuzhou Pharmaceutical Co Ltd

PeptiStar Inc.

Fujimoto Chemicals Co., Ltd.

The Merck Group

Leadgene Biomedical

Lonza Group

APD Pharmaceutical

NeoBioLab Co., Ltd.

Apical Scientific Sdn Bhd

Hybio Pharmaceutical Co. Ltd

Senn Chemicals

Apex Biotechnology Corporation

Big Bear Pharmaceutical Co., Ltd.

Huarong Pharm

Bristo Pharmaceutical Company Canada

CEM Corporation

AnaSpec Inc.

CSBio

Patheon

Dalton Pharma Services

Canada Peptide

Therapure BioPharma Inc.

BCN Peptides

Axplora

Olon S.p.A.

Azenta Life Sciences

Aspen Pharmacare

Eva Pharma

Emzor Pharmaceuticals

Fidson Healthcare Plc

Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Drivers

The key drivers of the peptide therapeutics contract API manufacturing market include: Rising Prevalence Of Chronic And Metabolic Diseases The rising prevalence of chronic and metabolic diseases is driving demand for dark factories. Many chronic conditions require long-term, targeted, and biologically specific treatments, which aligns well with peptide-based drug modalities. As pharmaceutical and biotechnology companies expand their development programs to address growing patient populations, the need for reliable and scalable peptide API supply increases across preclinical, clinical, and commercial stages. This growth places pressure on internal manufacturing resources, encouraging sponsors to rely on specialized CDMOs that possess established peptide synthesis, purification, and GMP compliance capabilities. As disease prevalence rises, development portfolios become broader and more complex, reinforcing sustained outsourcing demand for high-quality peptide APIs that can support multiple programs simultaneously while meeting stringent regulatory requirements. The rising prevalence of chronic and metabolic diseases growth contribution during the forecast period in 2025 is 1.5%.

Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Restraints

The key restraints on the peptide therapeutics contract API manufacturing market include: Capacity And Scalability Limitations The capacity and scalability limitations remains a significant barrier to market expansion. Peptide manufacturing infrastructure involves capital-intensive synthesis reactors, purification systems, and controlled production environments that cannot be easily or rapidly expanded. As a result, CDMOs may face constraints in scaling production volumes, especially when multiple clients require simultaneous scale-up or commercial supply. Limited scalability can lead to longer lead times, delayed project transitions from clinical to commercial stages, and prioritization challenges among customers. These constraints reduce flexibility for pharmaceutical developers and can discourage outsourcing if manufacturers are unable to guarantee timely capacity availability, thereby slowing overall market growth. Growth affected by capacity and scalability limitations during the forecast period in 2025 is -2.0%.

Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Trends

Major trends shaping the peptide therapeutics contract API manufacturing market include: Expansion Of Flexible Peptide API Manufacturing Capabilities To Support Preclinical And Clinical Development Pipelines Major companies in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market are focusing on expanding flexible manufacturing capabilities that support early-stage preclinical and clinical peptide drug development. This trend helps pharmaceutical and biotech customers streamline preclinical and early clinical supply needs by integrating advanced manufacturing technologies, quality control, and regulatory support under one contract platform. For instance, in March 2024, CordenPharma, a Switzerland-based full-service contract development and manufacturing organization, announced the expansion of its early clinical peptide manufacturing operations at its Frankfurt site, launching new IND-targeted peptide API production services that include integrated support for peptide drug substance and injectable formulations to enable efficient investigational new drug (IND) or investigational medicinal product dossier (IMPD) filings and first-in-human clinical trials. Scaling Of Commercial-Grade Peptide API Manufacturing Infrastructure To Meet Growing Global Therapeutic Demand Companies operating in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market are focusing on scaling commercial-grade manufacturing infrastructure by launching expanded facilities capable of large-volume, Good Manufacturing Practice (GMP)-compliant peptide API production. This trend enables contract manufacturers to offer higher throughput, broader synthesis capabilities, and accelerated regulatory transfer for commercial supply while strengthening global customer partnerships. For instance, in January 2024, WuXi AppTec, a China-based global provider of contract research, development, and manufacturing organization (CRDMO), launched its new Taixing active pharmaceutical ingredient (API) manufacturing facility in Jiangsu, China as part of an expansion that included two new peptide plants at its Changzhou and Taixing sites, increasing its total solid-phase peptide synthesis (SPPS) reactor volume to 32,000 liters and enhancing capacity to meet surging global peptide therapeutic demand; the Taixing site, spanning 169 acres with multiple dedicated API production plants, further supports worldwide peptide API manufacturing for commercial supply.

Opportunities And Recommendations In The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

Opportunities – The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation will arise in the commercial segment, which will gain $3,284.2 million of global annual sales by 2030. The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method will arise in the chemical synthesis segment, which will gain $3,391.8 million of global annual sales by 2030. The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type will arise in the large enterprise segment, which will gain $2,674.3 million of global annual sales by 2030. The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market size will gain the most in the USA at $351.6 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing companies to focus on expanding flexible early-stage manufacturing capabilities, focus on scaling commercial-grade peptide API manufacturing capacity, focus on adopting integrated end-to-end peptide API manufacturing platforms, focus on advancing high-purity solid-phase peptide synthesis (SPPS) capabilities, focus on adopting hybrid peptide synthesis approaches, focus on strengthening GMP-compliant peptide API production, focus on expanding commercial-scale peptide API manufacturing, focus on expanding non-chemical peptide API manufacturing, expand in emerging markets, continue to focus on developed markets, focus on value-based and tiered pricing strategies, focus on targeted scientific marketing and thought leadership, focus on strategic client engagement and relationship marketing and focus on supporting small and medium enterprise clients.